Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-16T10:26:17.339Z Has data issue: false hasContentIssue false

Making a medicine out of MDMA

Published online by Cambridge University Press:  02 January 2018

Ben Sessa
Affiliation:
Weston-Super-Mare, and Cardiff University
David Nutt
Affiliation:
Neuropsychopharmacology Unit, Division of Brain Sciences, Faculty of Medicine, Imperial College London, UK
Rights & Permissions [Opens in a new window]

Summary

From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has beenrecognised as a drug with therapeutic potential. Research on its clinicalutility stopped when it entered the recreational drug scene but has slowlyresurrected in the past decade. Currently there is enough evidence for MDMAto be removed from its Schedule 1 status of ‘no medical use’ and moved intoSchedule 2 (alongside other misused but useful medicines such as heroin andamphetamine). Such a regulatory move would liberate its use as a medicinefor patients experiencing severe mental illnesses such astreatment-resistant post-traumatic stress disorder.

Information

Type
Editorials
Copyright
Copyright © Royal College of Psychiatrists, 2015 

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.